Business
Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors
MOUNTAIN VIEW, Calif., May 28, 2026--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Andrew Miller, Ph.D. to its Board of Directors, effective May 27, 2026.
About this update from Alto Neuroscience, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1659,"height":537,"url":"https://media.zenfs.com/en/business-wire.com/d183ae8bbc0b02951a77a1307f15748c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Upb6xuvWAEL952C6ExrEMw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMxMQ--/https://media.zenfs.com/en/business-wire.com/d183ae8bbc0b02951a77a1307f15748c","width":960,"height":311},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/h2U_oPWK_f8ELZ9lRu70fg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTIwNw--/https://media.zenfs.com/en/business-wire.com/d183ae8bbc0b02951a77a1307f15748c","width":640,"height":207},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/sj2NYyjz2MZSIo7aKcNLrw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03NzY-/https://media.zenfs.com/en/business-wire.com/d183ae8bbc0b02951a77a1307f15748c","width":1200,"height":388}},"lazy":false},{"type":"text","content":"Miller brings deep neuropsychiatry drug development and value creation experience, having led R&D at Karuna Therapeutics through its $14 billion acquisition by Bristol Myers Squibb","length":184,"tagName":"p","attribs":{}},{"type":"text","content":"MOUNTAIN VIEW, Calif., May 28, 2026--(BUSINESS WIRE)--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Andrew Miller, Ph.D. to its Board of Directors, effective May 27, 2026.","length":348,"tagName":"p"},{"type":"text","content":""We are thrilled to welcome Andrew to Alto’s Board at a transformative time for the Company," said Amit Etkin, M.D., Ph.D., Founder and Chief Executive Officer of Alto Neuroscience. "Few leaders in our industry have done more to advance the science and commercial reality of new medicines for serious mental illness. Andrew’s firsthand experience translating novel neuropsychiatric mechanisms into approved therapies — and building a category-defining company around them — will be invaluable as we execute on our potentially pivotal Phase 2b trial of ALTO-207 in treatment-resistant depression and advance multiple additional readouts across our precision psychiatry pipeline."","length":698,"tagName":"p"},{"type":"text","content":""Psyc...